Mitochondrial Pathology Clinical Trial
— CACTuS - TMZOfficial title:
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis
NCT number | NCT05633563 |
Other study ID # | 72864 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | October 1, 2021 |
Est. completion date | June 1, 2023 |
Verified date | April 2024 |
Source | Aarhus University Hospital Skejby |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Wild-type transthyretin cardiac amyloidosis (ATTRwt) is a deposition disorder in which one of the proteins of the body misfolds and accumulates at various places in the body, including the heart, leading to both mechanical and cellular damage. The gradual development of the disease will ultimately lead to heart failure and death The protein which deposits in the heart of patients, damages both the heart mechanically as the myocardium becomes rigid and hypertrophic over time but also at the cellular level. Cell damage can be observed by elevated blood tests for cell damage (Troponin) and during exercise tests that show patients' hearts burning oxygen inefficiently when exposed to physical stress compared with the hearts of healthy individuals . No one has, however, intimately studied this cellular damage. Vastarel® (Trimetazidine, TMZ) is an already known drug for the treatment of chest pain. The mechanism of action indicates that it may have an effect on patients with cardiac amyloidosis. The study aims to investigate the effects of TMZ on the mitochondrial function, myocardial performance, and invasive hemodynamics in patients with ATTRwt with a randomized, double-blinded, crossover-trial.
Status | Completed |
Enrollment | 24 |
Est. completion date | June 1, 2023 |
Est. primary completion date | June 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Wild-type transthyretin cardiac amyloidosis - NAC stage I - NYHA class of I or II - Informed consent Exclusion Criteria: - Other, similar diagnoses - Hereditary transthyretin cardiac amyloidosis - Light chain amyloidosis - Morbus Waldenstrøm - Myelomatosis - Medical treatment with loop diuretics in standard doses (40 mgx1 daily) - Contraindications to trimetazidine - Significant comorbidity assessed by the investigators - Unable to provide informed consent |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital, Department of Cardiology | Aarhus N | Danmark |
Lead Sponsor | Collaborator |
---|---|
Steen Hvitfeldt Poulsen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change: pulmonary capillary wedge pressure (PCWP) | We hypothesize a change in PCWP of 5 mmHg between the active drug and placebo using right heart catheterization. | Four weeks of treatment | |
Secondary | Change: cardiac index (CI) | We hypothesize a change in CI of 0.5 L/min between the active drug and placebo using right heart catheterization. | Four weeks of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03704311 -
Evaluation of Mitochondrial Function in Myofascial Trigger Points Cohort Pilot Study Using High-resolution Respirometry
|
N/A | |
Completed |
NCT03344913 -
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis
|
N/A | |
Not yet recruiting |
NCT04379934 -
Functional and Metabolic Effects of Ketone Bodies on Human Atrial Tissue in Patients With and Without Heart Failure
|
N/A | |
Not yet recruiting |
NCT04322734 -
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
|
||
Active, not recruiting |
NCT05162768 -
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
|
Phase 3 |